All In Biotech

Drug Trial Radar · NCT03984097

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jul 29, 2019

Primary completion

Mar 25, 2026

Study completion Mar 25, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.

Conditions

  • Multiple Myeloma

Interventions

  • TAK-079Drug

    TAK-079 subcutaneously.

  • LenalidomideDrug

    Lenalidomide orally.

  • DexamethasoneDrug

    Dexamethasone orally.

  • BortezomibDrug

    Bortezomib subcutaneously.

  • PomalidomideDrug

    Pomalidomide orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Phase: RP2D of TAK-079Time frame: Up to Cycle 1 (Cycle length is equal to [=] 28 days)
  2. Safety Extension Phase: Number of Participants Reporting one or More Serious Adverse Events (SAEs)Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
  3. Safety Extension Phase: Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
  4. Safety Extension Phase: Number of Participants Who Require Dose ModificationTime frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
  5. Safety Extension Phase: Number of Participants With TEAEs Leading to Treatment DiscontinuationTime frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • Pacific Cancer Care

    Monterey, California

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Columbia University Medical Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Good Samaritan Hospital

    Cincinnati, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • MD Anderson Cancer Center

    Houston, Texas

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.